,drugId,displayName,indication,company,country,probabilityOfSuccess,phase,startDate,endDate,successPercentage
3,54730,sotatercept,Pulmonary artery hypertension,Merck & Co Inc,US,92%,Phase 2,13-Jun-2018,25-Jan-2021,
4,54730,sotatercept,Pulmonary artery hypertension,Merck & Co Inc,US,92%,Phase 3,25-Jan-2021,30-Jun-2023,
5,54730,sotatercept,Pulmonary artery hypertension,Merck & Co Inc,US,92%,Pre-Reg,30-Jun-2023,25-Mar-2024,92%
6,54730,sotatercept,Pulmonary artery hypertension,Merck & Co Inc,US,92%,Reg,25-Mar-2024,,
